Evidence map›Paper›PMID 34023515›Full record

ArticleContemporary clinical trials2021

The Head and Neck Survivorship Tool (HN-STAR) Trial (WF-1805CD): A protocol for a cluster-randomized, hybrid effectiveness-implementation, pragmatic trial to improve the follow-up care of head and neck cancer survivors.

Talya Salz, Jamie S Ostroff, Chandylen L Nightingale, Thomas M Atkinson, Eleanor C Davidson, Sankeerth R Jinna, Anuja Kriplani, Glenn J Lesser, Kathleen A Lynch, Deborah K Mayer and 4 more

Open access · greenAbstract readClinical Trial Protocol
In one paragraph

Article in Contemporary clinical trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Survivorship therapy needs after radiotherapy for head and neck cancer: surveying opportunities for growth (STRONG).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Talya SalzMemorial Sloan Kettering Cancer Center, 1275 York Street, New York, NY 10065, USA. Electronic address: salzt@mskcc.org.
Jamie S OstroffMemorial Sloan Kettering Cancer Center, 1275 York Street, New York, NY 10065, USA.
Chandylen L NightingaleWake Forest School of Medicine, Department of Social Sciences & Health Policy, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Thomas M AtkinsonMemorial Sloan Kettering Cancer Center, 1275 York Street, New York, NY 10065, USA.
Eleanor C DavidsonWake Forest School of Medicine, Department of Social Sciences & Health Policy, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Sankeerth R JinnaMemorial Sloan Kettering Cancer Center, 1275 York Street, New York, NY 10065, USA.
Anuja KriplaniMemorial Sloan Kettering Cancer Center, 1275 York Street, New York, NY 10065, USA.
Glenn J LesserWake Forest School of Medicine, Department of Social Sciences & Health Policy, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Kathleen A LynchMemorial Sloan Kettering Cancer Center, 1275 York Street, New York, NY 10065, USA.
Deborah K MayerUniversity of North Carolina Lineberger Comprehensive Cancer Center, 450 West Dr, Chapel Hill, NC 27599, USA.
Kevin C OeffingerDuke Cancer Institute, 2424 Erwin Dr, Suite 601, Durham, NC 27705, USA.
Sujata PatilThe Cleveland Clinic Foundation, 9500 Euclid Avenue, CA6-160, Cleveland, OH 44195, USA.
Andrew L SalnerHartford HealthCare Cancer Institute at Hartford Hospital, 79 Retreat Ave, Hartford, CT 06106, USA.
Kathryn E WeaverWake Forest School of Medicine, Department of Social Sciences & Health Policy, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Memorial Sloan Kettering Cancer Center · USWake Forest University · USCleveland Clinic · USDuke Cancer InstituteHartford Hospital · USUNC Lineberger Comprehensive Cancer Center

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Wake Forest NCORP Research BaseUG1CA189824 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Emily Van Meter Dressler, GLENN J LESSER · 2014 to 2026
$57.9M
Wake Forest Clinical and Translational Science AwardKL2TR001421 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MILLER, DAVID P · 2015 to 2023
$5.8M
NCATS NIH HHS KL2 TR001421NCI NIH HHS P30 CA008748NCI NIH HHS UG1 CA189824
6 · The paper itself

Abstract

Survivors of head and neck cancer (HNC) can have multiple health concerns. To facilitate their care, we developed and pilot-tested a clinical informatics intervention, HN-STAR. HN-STAR elicits concerns online from HNC survivors prior to a routine oncology clinic visit. HN-STAR then presents tailored evidence-based clinical recommendations as a clinical decision support tool to be used during the visit where the oncology clinician and survivor select symptom management strategies and other actions. This generates a survivorship care plan (SCP). Online elicitation of health concerns occurs 3, 6, and 9 months after the clinic visit, generating an updated SCP each time. HN-STAR encompasses important methods of improving survivorship care (e.g., needs assessment, tailored interventions, dissemination of guidelines) and will be evaluated in a pragmatic trial to maximize external validity. This hybrid type 1 implementation-effectiveness trial tests HN-STAR effectiveness while studying barriers and facilitators to implementation in community oncology practices within the National Cancer Institute Community Oncology Research Program. Effectiveness will be measured as differences in key survivorship outcomes between HNC participants who do and do not use HN-STAR over one year after the clinic visit. The primary endpoint is HNC-specific quality of life; other outcomes include patient-centered measures and receipt of guideline-concordant care. Implementation outcomes will be assessed of survivors, providers, and clinic stakeholders. The hybrid design will provide insight into a dose-response relationship between the extent of implementation fidelity and effectiveness outcomes, as well as how to incorporate HN-STAR into standard practice outside the research setting.

Indexed as

Head and Neck NeoplasmsSurvivorshipAftercareHumansPragmatic Clinical Trials as TopicQuality of LifeRandomized Controlled Trials as TopicSurvivorsCancer survivorsHead and neck neoplasmsImplementation sciencePatient reported outcomes measuresRandomized controlled trialSurvivorship care plan

Identifiers

PMID34023515
PMCPMC8543489
OpenAlexW3164096110

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.